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Abstract 
Background Socioeconomic inequalities in colorectal cancer (CRC) survival are well recognised. 
The aim of this study was to describe the impact of socioeconomic deprivation on survival in patients 
with synchronous CRC liver-limited metastases, and to investigate if any survival inequalities are 
explained by differences in liver resection rates. 
 
Methods Patients in the National Bowel Cancer Audit diagnosed with CRC between 2010 and 2016 
in the English National Health Service were included. Linked Hospital Episode Statistics data were 
used to identify the presence of liver metastases and whether a liver resection had been performed. 
Multivariable random-effects logistic regression was used to estimate the odds ratio (OR) of liver 
resection by Index of Multiple Deprivation (IMD) quintile. Cox-proportional hazards model was used 
to compare 3-year survival. 
 
Results 13,656 patients were included, of whom 2,213 (16.2%) underwent liver resection. Patients in 
the least deprived IMD quintile were more likely to undergo liver resection than those in the most 
deprived quintile (adjusted OR 1.42, 95% confidence interval (CI) 1.18-1.70). Patients in the least 
deprived quintile had better 3-year survival (least deprived vs. most deprived quintile, 22.3% vs. 
17.4%; adjusted hazard ratio (HR) 1.20, 1.11-1.30). Adjusting for liver resection attenuated, but did 
not remove, this effect. There was no difference in survival between IMD quintile when restricted to 
patients who underwent liver resection (adjusted HR 0.97, 0.76-1.23).  
 
Conclusions Deprived CRC patients with synchronous liver-limited metastases have worse survival 
than more affluent patients. Lower rates of liver resection in more deprived patients is a contributory 
factor. 
 
Key words: 
Colorectal cancer; liver metastases; socioeconomic deprivation 
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1. Introduction 
Socioeconomic inequalities in survival have been reported for most adult cancers worldwide 1-3. Even 
in the United Kingdom (UK) where there is a universal entitlement to healthcare within the National 
Health Service (NHS), the health inequalities between the most deprived and least deprived areas of 
the country are showing little sign of reducing 4. The improved cancer survival that has occurred over 
the last two decades in the United Kingdom has been reflected more in patients living in affluent areas 
than for those living in deprived areas 5. It is estimated that 11 per cent of deaths from common 
cancers would be avoided if survival for all patients was as high as in the most affluent group 5. 
 
Colorectal cancer (CRC) is one of the most common malignancies in the Western world and the 
fourth most common cancer in the United Kingdom (UK) 6. There are over 40,000 new cases of CRC 
diagnosed per annum and CRC is the second most common cause of cancer-related deaths in the 
UK. Poorer cancer-specific and overall survival in CRC patients in lower socioeconomic groups has 
been reported in United States 7, European 8, 9 and UK 9-11 populations. The origins of these disparities 
in survival are not fully understood.  Although late stage at presentation is a commonly cited cause of 
the lower survival amongst more deprived patients 12, studies which correct for stage have reported 
that this difference remains 13.  Evidence now also points to both differential access to treatment and 
differential disease management within the healthcare system 14 . Access to specialist care is known to 
favour the affluent 15 and differences in rates of primary CRC resection 16-18 and receipt of 
chemotherapy 7, 19-21 according to socioeconomic status have been demonstrated.  
 
Synchronous liver metastases are present in around 20 per cent of patients diagnosed with CRC 22. 
Liver resection in suitable patients is the only curative treatment modality with 5-year survival rates 
from 44 to 74 per cent reported following resection 23-25. Relatively little is known about the impact of 
socioeconomic status on liver resection rates, with studies reporting conflicting findings. A study of 
selection for liver resection in an English CRC population diagnosed from 1998-2004 demonstrated 
higher socioeconomic status to independently predict liver resection 24.  Similarly, Wiggans and co-
authors. (2015), reported that affluent patients were over-represented amongst a regional English 
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cohort of patients undergoing liver resection when compared to the demographics of the local 
population 26.  In contrast, a population-based study of patients with synchronous liver-limited 
metastases in Sweden did not find either income or education to be independently associated with 
liver resection 27. No previous study has examined socioeconomic status as an independent predictor 
of mortality in this cohort. In this paper we describe the association between socioeconomic 
deprivation and the rate of liver resection and survival in patients with synchronous CRC liver 
metastases. We also investigate if any survival inequalities related to deprivation within this cohort 
are explained by differences in rates of liver resection. 
 
2. Methods 
2.1 Study population 
Data from patients included in the National Bowel Cancer Audit (NBOCA) 28 were linked to Hospital 
Episode Statistics (HES) data. NBOCA data is prospectively collected and submission of patient data 
for those with a new diagnosis of CRC is mandatory for NHS trusts in England. In this study we 
included all patients recorded in the NBOCA dataset with a diagnosis of primary CRC from 1st 
January 2011 to 31st December 2015 with synchronous liver-limited metastases. 
 
2.2 Study variables 
Diagnostic information is captured in HES according to ICD-10 29. Synchronous liver metastases and 
extra-hepatic metastases were defined as an ICD-10 code for secondary cancer within the liver (C787) 
or secondary cancer elsewhere (C780-784, C786, C790-96) recorded up to one year before and 30-
days after diagnosis of CRC. A year before CRC diagnosis was chosen to include patients who are 
found to have metastases before determining the site of the primary CRC. 
 
Admission type (elective or emergency) was obtained from the linked HES records. The Royal 
College of Surgeons Charlson co-morbidity score 30 was used to identify co-morbid conditions in the 
HES records in the preceding year.  
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Socioeconomic status was calculated by the English Indices of Deprivation according to the patient’s 
postcode 31. This is the official measure of relative deprivation for neighbourhoods in England. The 
Index of Multiple Deprivation (IMD) ranks every small area in England from 1 (most deprived area) 
to 32,844 (least deprived area). Every such neighbourhood covers an average population of around 
1500 people or 400 households. This measure is based on 37 indicators organised across 7 distinct 
domains of deprivation. These are combined to calculate the Index of Multiple Deprivation (IMD). 
The 7 domains of deprivation relate to 1) income, 2) employment, 3) education, 4) health and 
disability, 5) crime, 6) barriers to housing and services and 7) living environment. Quintiles are 
calculated by ranking the 32,844 small areas in England from most deprived to least deprived and 
dividing them into five equal groups.  
 
Liver metastases were identified in HES data because the NBOCA records only the presence, but not 
the site, of metastatic disease. Of all patients with CRC identified in the NBOCA database as having 
metastatic disease at diagnosis, 60 per cent had a metastases code recorded in HES data. Despite the 
potential under-reporting of liver metastases in HES, odds ratios still represent a valid measure of the 
relationship between patient characteristics and the liver resection rate, in the same way that an odds 
ratio provides a valid measure of relative risk in case–control studies. This is valid as long as under-
recording is not dependent on the risk factor under investigation (socioeconomic status).  The use of 
patients with recorded liver metastases in HES as a representative sample of all patients with liver 
metastases has been previously validated by comparing the characteristics of patients with metastases, 
irrespective of their site, identified in the NBOCA database and corresponding patients in the HES 
database 32. 
 
Procedure information is captured in HES according to OPCS-4 33. All HES records in the year 
following the date of CRC diagnosis were searched for codes indicating a liver resection: right 
hemihepatectomy (J021), left hemihepatectomy (J022), resection of segment of liver (J023), wedge 
excision of liver (J024), extended right hemihepatectomy (J026), extended left hemihepatectomy 
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(J027), partial excision of liver (J028/9), excision of lesion of liver (J031) and extirpation of lesion of 
liver (J038/9).  
 
2.3 Study endpoints 
The primary endpoints were receipt of liver resection within one year of date of CRC diagnosis and 
three-year all cause survival from date of CRC diagnosis. These two outcomes as well as 
demographic and tumour characteristics were compared between IMD quintiles to highlight any 
differences between groups of decreasing deprivation.  
 
2.4 Statistical analysis 
The statistical significance of differences in patient characteristics according to IMD quintile were 
assessed using the χ2 test.  Multivariable random-effects logistic regression was used to estimate the 
odds ratio of liver resection by IMD quintile, firstly adjusted for the following risk factors: gender, 
age, Charlson co-morbidity score, primary cancer site within the colon and rectum, admission type, T-
stage and N-stage. A further model was fitted additionally adjusting for the presence of hepatobiliary 
surgical services on-site. A random intercept was modelled for each hospital trust to reflect the 
possible clustering of results within trusts. Missing values for the risk factors were imputed with 
multiple imputation using chained equations, creating ten data sets and using Rubin's rules to combine 
the estimated odd ratios across the data sets. Survival curves were estimated using the Kaplan–Meier 
method. Difference in 3-year survival in the first three years after diagnosis between IMD quintiles 
was tested with the log rank test. Comparisons were made adjusting for other risk factors using a 
multivariable Cox proportional hazards model with a shared frailty factor, again to reflect the possible 
clustering of results within hospitals. STATA® version 14.1 (StataCorp, College Station, Texas, USA) 
was used for all analyses. 
 
3. Results 
3.1 Study population 
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There were 18,899 patients out of the 130,554 patients diagnosed with primary CRC from 1st January 
2011 to 31st December 2015 with synchronous liver metastases (14.5 per cent) identified from 
NBOCA linked HES data. Of these, 5,243 patients were excluded due to recorded extra-hepatic 
metastases, resulting in a final cohort of 13,656 CRC patients with synchronous liver-limited 
metastases. This group formed the study population and their demographic data, divided into quintiles 
of deprivation, are summarized in Table 1. Patients in the lower socioeconomic quintiles tended to be 
younger, have more comorbidities, have rectal cancer, and more commonly had an emergency 
presentation leading to CRC diagnosis  
 
3.2 Liver resection 
Overall 2,213 out of 13,656 patients with synchronous liver-limited CRC metastases had a liver 
resection (16.2 per cent). Liver resection was performed more frequently in patients in the least 
deprived IMD quintile when compared to those in the most deprived quintile (18.7 per cent vs. 13.3 
per cent, p<0.001).  
 
With adjustment for differences in patient and institutional characteristics, patients in the least 
deprived quintile remained more likely to undergo liver resection than patients in the most deprived 
quintile, with a trend of increasing chance of liver resection with decreased quintile of deprivation 
(least deprived vs. most deprived IMD quintile OR 1.42, 95 per cent confidence interval (C.I.) 1.18 to 
1.70) (Table 2). 
 
3.3 Survival 
Median follow up was 45 months. There was a significant difference in all-patient survival, regardless 
of whether of liver resection was undertaken, according to IMD quintile. Three-year survival for 
patients in the most deprived quintile was 17.4 per cent compared to 22.3 per cent for patients in the 
least deprived quintile (p<0.001) (Table 3). There remained significant difference when risk adjusted 
for patient and institutional characteristics (least deprived vs. most deprived IMD quintile, hazard 
ratio (HR) 1.20, 95 per cent C.I. 1.11 to 1.30) (Table 4). Adding liver resection as a covariate in the 
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multivariable model attenuated, but did not remove, this effect (least deprived vs. most deprived IMD 
quintile HR 1.15, 95% C.I. 1.06 to 1.24).  
 
When survival analysis was restricted to patients undergoing a liver resection, there was no significant 
difference in unadjusted (Table 3) or adjusted (Table 4) survival according to IMD quintile. In 
patients not undergoing liver resection, patients in the least deprived group had better 3-year survival 
then those in the most deprived group (7.3 per cent vs. 9.3 per cent; P<0.001). This difference 
remained after adjusting for differences in patient characteristics.  
 
4. Discussion 
4.1 Principal findings 
Reducing health inequities in England has been a longstanding priority of the government with more 
than £20 billion spent between 1997 and 2007 on a dedicated strategy to target this 34. Moving 
forwards, the Cancer Research Taskforce for England which is working to develop a cancer survival 
improvement strategy on behalf of NHS England, has recommended that the tackling of 
socioeconomic variation is a top priority over the next five years 35. The relationship between cancer 
and socioeconomic status has been studied extensively, and it has been found that social factors 
strongly influence treatment and survival 5, 7-11. In this study we demonstrate socioeconomic 
deprivation to be associated with lower rates of liver resection and poorer 3-year survival amongst 
CRC patients with synchronous liver-limited metastases. This was irrespective of differences in 
demographic, tumour related and institutional factors. Socioeconomic deprivation was no longer 
associated with poorer outcomes when only patients undergoing liver resection were considered. 
 
4.2 Interpretation of results and comparison with other studies 
The findings in this study show that socioeconomic differences in survival in patients with CRC liver 
metastases can be explained in part by inequalities in treatment. These findings, which mirror those 
reported in non-metastatic CRC 36, ovarian cancer 37 and lung cancer 38 suggest equal treatment yields 
equal outcomes, regardless of deprivation. For patients who did not undergo liver resection, 
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socioeconomic deprivation continued to be associated with poorer survival after controlling for 
differences in patient and tumour characteristics. For this palliative cohort survival outcomes may 
relate to use of chemotherapy 7, 19-21, or enrolment in clinical trials 39, both reportedly lower in more 
deprived patients. Data regarding these variables were not available and therefore not included in the 
multivariable model.  
 
There are a number of obstacles to overcome for a patient with CRC liver metastases to undergo a 
liver resection. In patients undergoing the traditional bowel-first approach for resection of liver 
metastases, they must survive the resection of their primary tumour, they must recover sufficiently 
from this operation to potentially undergo further surgery, they must be referred to a hepatobiliary 
multidisciplinary team (MDT) for consideration of surgical resection and finally their metastases must 
be deemed operable. A patient’s socioeconomic status may influence how they negotiate this complex 
pathway. Within a publicly-funded health system it is an uncomfortable notion that socioeconomic 
status can influence treatment, and thus survival, for patients with CRC liver metastases. There are 
several mechanisms by way of which a patient’s socioeconomic status may influence rates of liver 
resection, including uptake of bowel cancer screening, stage of disease at presentation, presence of 
comorbidities, access to local services, clinical decision making and health-seeking behaviour.  
 
Although clinical and pathological characteristics in CRC patients are associated with both 
socioeconomic status and likelihood of liver resection, controlling for such differences did not 
account for the differences in liver resection rates. The presence of comorbidity, more prevalent in 
patients in lower socioeconomic groups in this study cohort, can impact upon a patient’s fitness for 
liver resection. After adjusting for differences however in Charlson comorbidity score, the association 
between less deprivation and increased likelihood of liver resection remained. Patients with higher 
levels of deprivation are also more likely to suffer post-operative complications and mortality related 
to primary CRC resection that render them unfit for liver resection 11. However, when patients who 
died within 90 days of major CRC resection were excluded in a sensitivity analysis, the difference in 
rates of liver resection remained. More advanced disease stage at diagnosis is often cited as a main 
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cause of inequality in cancer related treatment and outcomes according to social status 40. However 
this was not a factor in this study cohort, where there was no statistically significant difference in 
stage according to level of deprivation. 
 
Differences in liver resection rates according to socioeconomic status in this cohort may also relate to 
access to specialist care. This is particularly pertinent when considering services, such as 
hepatobiliary surgery, that exist in a centralised system. Several studies have now demonstrated that 
the presence of specialist hepatobiliary services on-site at the hospital trust of treatment increases liver 
resection rates amongst patients with CRC liver metastases 27, 41. Deprived patients were more 
commonly diagnosed at a hospital trust with no hepatobiliary services on site. Ability to travel for 
healthcare may be lower amongst more deprived patients and therefore the necessity to travel to 
access hepatobiliary services may preferentially disadvantage those of a lower socioeconomic status 
42
. However controlling for the on-site presence of specialist services in the study cohort did not 
reduce the effect of deprivation on likelihood of liver resection. In addition, there was no evidence of 
a different effect of deprivation in hospital trusts with and without on-site specialist services (results 
not shown), suggesting this is not the explanation for the finding. 
 
A patient’s socioeconomic status may also modify the behaviour of the treating clinicians and cause 
inequalities in access to specialist care. There is an element of discretion by clinician practitioners in 
many stages of the patient pathway prior to surgery for CRC liver metastases. Although few surgeons 
would admit to altering their management of patients due to deprivation, clinicians may consider more 
deprived patients to have a lack of social support 43, or be less able to travel to specialist services 42 
and therefore be less likely to refer these patients to a hepatobiliary MDT for consideration of liver 
resection. Finally, factors relating to a patient’s health seeking behaviour may partly explain 
differences in rates of liver resection. Low health literacy is associated with both poorer health 
outcomes and use of health care services 44. As a result, more deprived patients may be less likely to 
themselves seek referral to a hepatobiliary unit than more affluent patients 26.  
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4.3 Implications for policy 
Inequalities in receipt of liver resection amongst patients with CRC liver metastases appear to account 
in part for differences in patient survival. Future focus should therefore be on ensuring that more 
deprived patients have access to liver resection. The National Institute of Health and Clinical 
Excellence recommends for the management of metastatic CRC that if the secondary tumour is 
considered ‘resectable’ the patient should be considered for surgery 45. However, clinical guidelines 
for colorectal MDTs are often unclear about what should be considered ‘resectable’ disease, leaving 
referral practices to local policy and a clinician’s own judgement. Inequalities in tertiary referral 
related to deprivation, are reportedly more likely to occur in the absence of explicit clinical guidance 
46
, suggesting that the development of clearer referral guidelines for colorectal MDTs would help to 
reduce these differences.  
 
4.4 Strengths and Weaknesses 
This study benefits from the use of a national clinical audit, with mandatory data submission. NBOCA 
reports a colorectal cancer case ascertainment of 93.0 per cent 28.  However, we recognise the 
limitations of this work. HES data does not contain information regarding the distribution or size of 
liver metastases, an important factor in determining the operability of liver metastases. We were 
therefore unable to ascertain whether differences in liver resection rates reflected clinically 
appropriate decision making or inequity. In addition, around 20 per cent of T-stage and N-stage data 
is missing from NBOCA data. Importantly, there was no difference in proportion of missing data 
according to IMD quintile. Missing values were imputed using multiple imputation to minimise the 
bias associated with excluding patients with missing values.  As chemotherapy is usually administered 
on an outpatient basis, the HES dataset does not contain details regarding its provision. Adjuvant 
chemotherapy is less frequently used in more deprived patients and differences in its use may account 
in part for the reported variation in rates of liver resection and survival inequality in patients who did 
not undergo liver resection 7, 19-21.  A further limitation of HES is the under-reporting of liver 
metastases. Some 15 per cent of patients with CRC were found to have a HES code recorded for liver 
metastases at the time of diagnosis, whereas other population-based studies have reported 
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corresponding percentages of up to 20 per cent. However, as explained in section 2.2, the odds ratio 
can be used as a valid measure of the impact of socioeconomic status on resection rates as 
socioeconomic status does not affect the recording of metastases in HES 32.  
 
This study only includes patients undergoing liver resection in a NHS hospital. The inclusion of 
private patients, the majority of whom will be in the most affluent quintile, would likely make the 
liver resection rate, and therefore the survival differences between IMD quintiles, more pronounced. 
More details regarding the structure of hepatobiliary services in England may further explain the 
disparity observed. Liver resection rates amongst more deprived patients may be higher at sites which 
do not have hepatobiliary surgical services on-site but do conduct hepatobiliary outreach clinics, 
therefore reducing the travel burden for patients. 
 
5. Conclusions 
This study has demonstrated that more deprived CRC patients with synchronous liver metastases have 
worse survival than more affluent patients in England. Lower rates of liver resection in poorer CRC 
patients is likely to be a major contributory factor. As both the patient and tumour characteristics and 
institutional variables included in the multivariable model in this study did not account for the 
differences in liver resection rates according to socioeconomic status, this suggests that is it is 
differences in the availability of services or in decision making by socioeconomic status that account 
for the differences observed. Targeted efforts should be made by healthcare providers to ensure 
equitable access to specialist care for this cohort.  
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Table 1 Characteristics of patients according to IMD quintile for 13,656 patients diagnosed with 
colorectal cancer and synchronous liver-limited metastases colorectal cancer from 2010 to 2016 
 
    IMD quintile 
 
    
1 (most 
deprived) 
N=2,233 
(%) 
2 N=2,628 
(%) 
3 N=2,886 
(%) 
4 N=3,009 
(%) 
5 (least 
deprived) 
N=2,890 
(%) 
P-
value 
Sex Male 1,398 (62.6) 1,561 (59.4) 1,764 (61.1) 1,810 (60.2) 1,711 (59.2) 0.089 Female 835 (37.4) 1,067 (40.6) 1,222 (38.9) 1,199 (39.9) 1,179 (40.8) 
Age 
<65 830 (37.2) 889 (33.8) 1,004 (34.8) 888 (29.5) 934 (32.3) 
<0.001 65-74 671 (30.1) 752 (28.6) 846 (29.3) 915 (30.4) 829 (28.7) 
>74 732 (32.8) 987 (37.6) 1,036 (35.9) 1,206 (40.1) 1,127 (39.0) 
Site 
Right 762 (34.1) 871 (33.1) 1,015 (35.2) 1,130 (37.6) 1,074 (37.2) 
0.002 Left 886 (39.7) 1,100 (41.9) 1,196 (41.4) 1,190 (40.0) 1,110 (38.4) 
Rectum 585 (26.2) 657 (25.0) 675 (23.4) 689 (22.9) 706 (24.4) 
Charlson 
comorbidity 
score 
0 1,130 (55.4) 1,364 (56.5) 1,695 (63.5) 1,777 (64.1) 1,711 (65.3) 
<0.001 1 604 (29.6) 743 (30.8) 671 (25.1) 717 (25.9) 676 (25.8) 2 306 (15.0) 308 (12.8) 305 (11.4) 279 (10.1) 233 (8.9) 
Missing 193 213 215 236 270 
T-stage 
0-2 104 (6.1) 133 (6.6) 135 (6.0) 161 (6.9) 186 (7.9) 
0.17 3 880 (51.7) 1,043 (51.7) 1,164 (51.9) 1,203 (51.5) 1,262 (53.8) 4 719 (42.2) 842 (41.7) 943 (42.1) 970 (41.6) 898 (38.3) 
Missing 530 610 644 675 544 
N-stage 
0 340 (19.8) 461 (22.7) 473 (20.9) 501 (21.4) 502 (21.4) 
0.495 1 710 (41.4) 820 (40.3) 887 (39.1) 936 (39.9) 943 (40.1) 2 665 (38.8) 754 (37.1) 906 (40.0) 908 (38.7) 905 (38.5) 
Missing 518 593 620 664 540 
Emergency 
admission 
No 1,257 (61.7) 1,539 (63.8) 1,752 (65.5) 1,835 (66.2) 1,880 (71.3) 
<0.001 Yes 782 (38.4) 875 (36.3) 921 (34.5) 936 (33.8) 757 (28.7) 
Missing 194 214 213 238 253 
Hepatobiliary 
services on-site 
No 593 (26.6) 482 (18.3) 507 (17.6) 506 (16.8) 590 (20.4) 
<0.001 Yes 1,640 (73.4) 2,146 (81.7) 2,379 (82.4) 2,503 (83.2) 2,300 (79.6) 
Liver resection No 1,937 (86.7) 2,217 (84.4) 2,411 (83.5) 2,517 (83.7) 2,351 (81.4) <0.001 Yes 296 (13.3) 411 (15.6) 475 (16.5) 492 (16.4) 539 (18.7) 
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Table 2 Odds ratio of undergoing liver resection adjusted for patient, tumour and hospital 
characteristics 
 
 
 
  
  
  
Odds ratio (95% 
confidence 
interval) 
P-value 
Odds ratio (95% 
confidence 
interval) 
adjusted for 
patient and 
tumour 
characteristics 
P-value 
Odds ratio (95% 
confidence 
interval) 
adjusted for 
patient, tumour 
and hospital 
characteristics 
P-value 
IMD quintile 
1 (most deprived) 1 
<0.001 
1 
0.005 
1 
0.003 
2 1.21 (1.02-1.42) 1.22 (1.02-1.46) 1.24 (1.03 to 1.48) 
3 1.29 (1.10-1.52) 1.30 (1.09-1.56) 1.32 (1.1 to 1.58) 
4 1.30 (1.11-1.53) 1.29 (1.08-1.54) 1.30 (1.09 to 1.56) 
5 (least deprived) 1.47 (1.25-1.73) 1.41 (1.18-1.68) 1.42 (1.18 to 1.70) 
Gender Male - - 1 0.18 1 0.187 Female - - 1.07 (0.97-1.20) 1.07 (0.97 to 1.20) 
Age 
<65 - - 1 
<0.001 
1 
<0.001 65-74 - - 0.66 (0.59-0.74) 0.66 (0.59 to 0.74) 75-84 - - 0.32 (0.27-0.36) 0.31 (0.27 to 0.36) 
>=85 - - 0.07 (0.05-0.11) 0.07 (0.05 to 0.11) 
Emergency 
admission 
No - - 1 
<0.001 1 <0.001 Yes - - 0.44 (0.38-0.50) 0.44 (0.38 to 0.5) 
Charlson 
comorbidity 
score 
0 - - 1 
0.469 
1 
0.454 1 - - 0.99 (0.88-1.12) 0.99 (0.87 to 1.12) 
2 - - 0.89 (0.73-1.07) 0.88 (0.73 to 1.07) 
 Cancer site 
Right - - 1 
<0.001 
1 
<0.001 Left - - 1.21 (1.08-1.38) 1.22 (1.07 to 1.38) 
Rectum - - 0.96 (0.83-1.10) 0.96 (0.83 to 1.1) 
T-stage 
0-2 - - 1 
<0.001 
1 
<0.001 3 - - 1.11 (0.91-1.36) 1.1 (0.9 to 1.35) 
4 - - 0.84 (0.68-1.04) 0.84 (0.68 to 1.04) 
N-stage 
0 - - 1 
<0.001 
1 
<0.001 1 - - 0.62 (0.54-0.70) 0.62 (0.54 to 0.7) 
2 - - 0.41 (0.36-0.48) 0.42 (0.36 to 0.48) 
Hepatobiliary 
services on-
site 
No - - - 
- 
1 
0.003 Yes 
- - - 1.38 (1.12 to 1.7) 
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Table 3 Unadjusted 3-year survival from date of colorectal cancer diagnosis according to IMD 
quintile for all patients (P<0.001) and restricted to patients undergoing liver resection (P=0.742) and 
those not undergoing liver resection (P<0.001) 
 
 IMD quintile All patients Patients undergoing liver 
resection 
Patients not undergoing 
liver resection 
  
3-year survival % (95% CI) 
1 (most deprived) 17.4 (15.7-19.1) 65.5 (59.7-70.1) 7.3 (6.0-8.8) 
2 19.0 (17.4-20.7) 71.3 (66.7-75.4) 6.8 (5.6-8.0) 
3 19.0 (17.4-20.5) 67.7 (63.2-71.8) 7.2 (6.1-8.4) 
4 19.5 (18.0-21.1) 69.0 (54.6-72.9) 7.8 (6.5-8.9) 
5 (least deprived) 22.3 (20.7-24.0) 69.3 (65.1-73.2) 9.3 (8.0-10.7) 
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Table 4 Hazard ratio of 3-year survival after colorectal cancer diagnosis adjusted for demographic, 
tumour and intuitional factors, for all patients and restricted to patients undergoing liver resection 
 
    
All patients 
(95% CI) P-value 
Liver resection 
patients 
(95% CI) 
P-value 
No liver resection 
patients 
(95% CI) 
P-value 
IMD quintile 
1 (most deprived) 1 
<0.001 
1 
0.568 
1 
<0.001 
2 1.05 (0.97 to 1.14) 1.02 (0.79 to 1.32) 0.98 (0.91 to 1.06) 
3 1.08 (0.99 to 1.15) 0.89 (0.7 to 1.14) 1.02 (0.93 to 1.1) 
4 1.14 (1.05 to 1.23) 0.93 (0.74 to 1.19) 1.1 (1.01 to 1.19) 
5 (least deprived) 1.20 (1.11 to 1.30) 0.97 (0.76 to 1.23) 1.16 (1.08 to 1.27) 
Gender 
Male 1 
0.22 
1 
0.572 
1 
0.142 
Female 0.97 (0.93 to 1.02) 0.93 (0.8 to 1.06) 0.96 (0.92 to 1.01) 
Age 
<65 1 
<0.001 
1 
<0.001 
1 
<0.001 
65-74 0.78 (0.74 to 0.82) 0.89 (0.76 to 1.05) 0.85 (0.8 to 0.91) 
75-84 0.5 (0.47 to 0.53) 0.65 (0.53 to 0.79) 0.62 (0.58 to 0.66) 
>=85 0.31 (0.47 to 0.53) 0.3 (0.17 to 0.52) 0.45 (0.49 to 0.49) 
Emergency 
admission 
No 1 
<0.001 
1 
<0.001 
1 
<0.001 
Yes 0.56 (0.53 to 0.59) 0.69 (0.57 to 0.83) 0.63 (0.6 to 0.66) 
Charlson 
comorbidity 
score 
0 1 
<0.001 
1 
0.484 
1 
<0.001 1 0.95 (0.9 to 1) 0.93 (0.78 to 1.1) 0.93 (0.88 to 0.99) 
2 0.85 (0.79 to 0.91) 0.79 (0.61 to 1.04) 0.85 (0.79 to 0.92) 
Cancer site 
Right 1 
<0.001 
1 
0.003 
1 
<0.001 Left 1.22 (1.16 to 1.28) 1.32 (1.11 to 1.56) 1.15 (1.09 to 1.22) 
Rectum 1.10 (1.04 to 1.18) 0.99 (0.81 to 1.2) 1.14 (1.06 to 1.2) 
T-stage 
0-2 1 
<0.001 
1 
0.022 
1 
0.012 3 1.05 (0.95 to 1.16) 0.71 (0.51 to 0.98) 1.06 (0.96 to 1.18) 
4 0.91 (0.83 to 1.01) 0.57 (0.41 to 0.81) 0.99 (0.88 to 1.1) 
N-stage 
0 1 
<0.001 
1 
<0.001 
1 
<0.001 1 0.69 (0.65 to 0.74) 0.64 (0.53 to 0.78) 0.79 (0.74 to 0.85) 
2 0.56 (0.52 to 0.6) 0.49 (0.4 to 0.6) 0.69 (0.65 to 0.75) 
Hepatobiliary 
services on-
site 
No 1 
0.04 
1 
0.411 
1 
0.215 
Yes 1.10 (1.00 to 1.20) 0.92 (0.77 to 1.09) 1.06 (0.97 to 1.15) 
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